The progressive decrease in MCT2 and increase in MCT4 expression from non-neoplastic tissues to metastatic lesions suggest that these transporters may serve as biomarkers for HCC progression and potential therapeutic targets. Here, SLC16A3 is linked to hepatocellular carcinoma.